The ‘cephalosporin era’ of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections

Bibliography

• Chapman SW, Sullivan DC, Cleary JD. In search of the holy grail of antifungal therapy. Trans Am Clin Climatol Assoc 2008;119:197-215
   PubMedGoogle Scholar
• Van der Linden JW, Camps SM, Kampinga GA, et al. Aspergillosis due to voriconazole highly resistant aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013;57:513-20
   PubMed Web of Science ®Google Scholar
• Maertens J, Cornely OA, Ullmann AJ, et al. Phase 1b study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother 2014;58:3610-17
   PubMed Web of Science ®Google Scholar
• Duarte RF, Lopez-Jimenez J, Cornely OA, et al. Phase 1b study of new posaconazole tablet for the prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 2014;58:5758-65
   PubMed Web of Science ®Google Scholar
• Turel O. Newer antifungal agents. Expert Rev Anti Infect Ther 2011;9:325-38
   PubMed Web of Science ®Google Scholar
• Castanheira M, Rhomberg P, Jones R, et al. Activity of a novel echinocandin biafungin (sp 3025) tested against most common candida and aspergillus species, including echinocandin and azole-resistant strains. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014, Washington
   Google Scholar
• Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol 2012;8:759-65
   PubMed Web of Science ®Google Scholar
• Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist 2013;6:163-74
   PubMedGoogle Scholar
• Maertens J PJ, Rahav G, et al. A phase 3 randomized, double-blind trial evaluating isavuconazole vs. voriconazole for the primary treatment of invasive fungal disease caused by aspergillus spp. or other filamentous fungi (SECURE). 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2013, Barcelona.
   Google Scholar
• Astellas Pharma. US FDA advisory committee briefing documemt: isavuconazonium oral and intravenous formulations. invasive aspergillosis and invasive mucormycosis. 2015. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM430748.pdf [Last accessed 22 February 2015]
   Google Scholar
• Astellas Pharma. FDA grants orphan drug designation to astellas for isavuconazole for the treatment of invasive candidiasis isavuconazole granted orphan drug designation by US FDA. Astellas Pharma; 2014
   Google Scholar
• Astellas Pharma. Astellas reports that isavuconazole granted orphan drug designation by US FDA. Astellas Pharma; 2013
   Google Scholar
• Basilea Pharma. Basilea reports that isavuconazole received QIDP designation by U.S. FDA for the treatment of invasive candidiasis. Basilea Pharma; 2014
   Google Scholar
• Basilea Pharma. Reports FDA’s Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis. Basilea Pharma; 2015
   Google Scholar
• Thompson GR3rd, Wiederhold NP. Isavuconazole: A comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010;170:291-313
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006;50:279-85
   PubMed Web of Science ®Google Scholar
• Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009;18:1279-95
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Inagaki Y, Fujii T, et al. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from japan. Int J Antimicrob Agents 2010;36:324-31
   PubMed Web of Science ®Google Scholar
• Katragkou A, Pana Z-D, Perlin DS, et al. Exserohilum infections: Review of 48 cases before the 2012 United States Outbreak. Med Mycol 2014;52:376-86
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Isavuconazole MIC distributions and epidemiological cutoff values for the cryptococcus neoformans-cryptococcus gattii species complex by the clsi broth microdilution method (M27-A3 document): A multicenter study. Antimicrob Agents Chemother 2014;58:2006-12
   PubMed Web of Science ®Google Scholar
• Gonzalez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 2009;47:71-6
   PubMed Web of Science ®Google Scholar
• Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008;52:1396-400
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Lechner V, Lass-Florl C. In vitro activity of isavuconazole against aspergillus species and zygomycetes according to the methodology of the european committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009;53:1645-7
   PubMed Web of Science ®Google Scholar
• Luo G, Gebremariam T, Lee H, et al. Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother 2014;58:2450-3
   PubMed Web of Science ®Google Scholar
• Seifert H, Aurbach U, Stefanik D, et al. In vitro activities of isavuconazole and other antifungal agents against candida bloodstream isolates. Antimicrob Agents Chemother 2007;51:1818-21
   PubMed Web of Science ®Google Scholar
• Castanheira M, Messer SA, Rhomberg PR, et al. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: Application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia 2014;178:1-9
   PubMed Web of Science ®Google Scholar
• Pfaller MA MS, Dietrich R, Rhomberg RR, et al. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: Application of new clinical breakpoints and epidemiological cutoff values Poster [M-1091]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014, Washington
   Google Scholar
• Thompson GRIII, Wiederhold NP, Fothergill AW, et al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2009;53:309-11
   PubMed Web of Science ®Google Scholar
• Thompson GRIII, Fothergill AW, Wiederhold NP, et al. Evaluation of etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2008;52:2959-61
   PubMed Web of Science ®Google Scholar
• Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, et al. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008;52:1580-2
   PubMed Web of Science ®Google Scholar
• Datta K, Rhee P, Byrnes EIII, et al. Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. J Clin Microbiol 2013;51:3090-3
   PubMed Web of Science ®Google Scholar
• Thompson GRIII, Wiederhold NP, Sutton DA, et al. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother 2009;64:79-83
   PubMed Web of Science ®Google Scholar
• Guinea J, Recio S, Escribano P, et al. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob Agents Chemother 2010;54:4012-15
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole bal4815, the active component of BAL 8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006;57:135-8
   PubMed Web of Science ®Google Scholar
• Shivaprakash MR, Geertsen E, Chakrabarti A, et al. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses 2011;54:583-9
   Web of Science ®Google Scholar
• Rudramurthy SM, Chakrabarti A, Geertsen E, et al. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the european committee on antimicrobial susceptibility testing. Diagn Microbiol Infect Dis 2011;71:370-7
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. For the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother 2013;57:3823-8
   PubMed Web of Science ®Google Scholar
• Verweij PE, Gonzalez GM, Wiedrhold NP, et al. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother 2009;21:272-81
   PubMed Web of Science ®Google Scholar
• Guinea J, Recio S, Pelaez T, et al. Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era. Antimicrob Agents Chemother 2008;52:3444-6
   PubMed Web of Science ®Google Scholar
• Kloezen W, Meis JF, Curfs-Breuker I, et al. In vitro antifungal activity of isavuconazole against Madurella mycetomatis. Antimicrob Agents Chemother 2012;56:6054-6
   PubMed Web of Science ®Google Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc 2011;86(8):805-17
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S RA, Melchers W, Mouton J, et al. In vitro activity of isavuconazole compared with itraconazole, voriconazole, and posaconazole in azole-resistant Aspergillus fumigatus Poster [M-1377]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2013, Denver
   Google Scholar
• Gregson L, Goodwin J, Johnson A, et al. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole. Antimicrob Agents Chemother 2013;57:5778-80
   PubMed Web of Science ®Google Scholar
• Jimenez-Ortigosa C MS, Fouant MM, Kovanda L, et al. Assessing isavuconazole induced resistance in Aspergillus fumigatus Poster [M-1081]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014, Washington
   Google Scholar
• Chandra J MP, Ghannoum MA. Resistance mechanisms to azoles in moulds Poster [M-1278]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014, Washington
   Google Scholar
• Petraitis V MM, Meletiadis JM, et al. In vitro combination therapy with isavuconazole against Candida spp Poster [M-1106]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014, Washington
   Google Scholar
• Katragkou A, McCarthy M, Meletiadis J, et al. In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds. Antimicrob Agents Chemother 2014;58:6934-7
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Parmar A, et al. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother 2009;53:3453-61
   PubMed Web of Science ®Google Scholar
• Majithiya J, Sharp A, Parmar A, et al. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 2009;63:161-6
   PubMed Web of Science ®Google Scholar
• Petraitiene R PV, Moradi P, Strauss G, et al. Pharmacokinetics and efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis Poster [M-759]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. American Society for Microbiology; 2013, Denver
   Google Scholar
• Box H GL, Livermore JL, Felton T, et al. Pharmacodynamics of isavuconazole for invasive pulmonary aspergillosis Poster [A-698]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014, Washington
   Google Scholar
• Warn PA, Sharp A, Mosquera J, et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother 2006;58:1198-207
   PubMed Web of Science ®Google Scholar
• Najvar LK WN, Bocanegra R, Olivo M, et al. Isavuconazole is effective for the treatment of experimental cryptococcal meningitis Poster [M-427]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014, Washington
   Google Scholar
• Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother 2009;53:4885-90
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffman A RB, Spickerman J, et al. No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data. 48th international interscience conference on antimicrobial agents and chemotherapy (ICAAC).American Society for Microbiology; 2008, Washington
   Google Scholar
• Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006;50:286-93
   PubMed Web of Science ®Google Scholar
• Cornely OA, Böhme A, Schmitt-Hoffmann A, et al. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrobial Agents Chemother 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Desai A, Kowalski D, Lu Q, et al. Isavuconazole population pharmacokinetic modeling from phase 1 and phase 3 clinical trials and target attainment analysis. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; 2014, Washington
   Google Scholar
• Yamazaki T PH, Kowalski DL, Lademacher C, et al. Effect of multiple doses of ketoconazole on the pharmacokinetics of isavuconazole in healthy subjects. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC). American Society for Microbiology; 2014, Washington
   Google Scholar
• Desai A BN, Yamazaki T, Kowalski D, et al. Isavuconazole dose not significantly affect the pharmacokinetics of p-glycoprotein substrate digoxin in healthy subjects. American Society for Clinical Pharmacology and Therapeutic Meeting; 2013, Indianapolis
   Google Scholar
• Yamazaki T PH, Desai A, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of cyp3A4 substrate cyclosporine in healthy subjects IN. American Society for Clinical Pharmacology and Therapeutic Meeting; 2014. Indianapolis
   Google Scholar
• Desai A HC, Yamazaki T, Kowalski D, et al. Isavuconazole does not affect prednisolone pharmacokinetics in healthy subjects following co-administration of multiple doses of isavuconazole. American Society for Clinical Pharmacology and Therapeutic Meeting; 2014, Indianapolis
   Google Scholar
• Desai A PH, Yamazaki T, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of cyp3A4 substrate tacrolimus in healthy subjects. IN: American Society for Clinical Pharmacology and Therapeutic Meeting; 2014, Indianapolis
   Google Scholar
• Yamazaki T DA, Kowalski D: Effect of multiple doses of isavuconazole on the pharmacokinetics of methotrexate in healthy subjects. American Society for Clinical Pharmacology and Therapeutic Meeting; 2014, Atlanta
   Google Scholar
• Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother 2015;59:1671-9
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813-21
   PubMed Web of Science ®Google Scholar
• Marr K BE, Heinz W, Lee M, et al. A phase 3 randomized, double-blind, non-inferiority trial evaluating isavuconazole vs. voriconazole for the primary treatment of invasive mold infection (SECURE): Outcomes in subset of patients with hematologic malignancies Poster [M-1757]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014, Washington
   Google Scholar
• Ullmann AJ SS, Huang W, Mujais S, et al. A phase 3 randomized,double-blind, non-inferiority trial evaluating isavuconazole vs. voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other filamentous fungi (SECURE): outcomes by malignancy status Poster [M-1756]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC). American Society for Microbiology; 2014, Washington
   Google Scholar
• Andes D GM, Kovanda L, Huang W, et al. Outcomes by minimum inhibitory concentrations from isavuconazole phase 3 trial of invasive aspergillosis (SECURE). Pharmacodynamics of isavuconazole for invasive pulmonary aspergillosis Poster [M-1761]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC). American Society for Microbiology; 2014, Washington
   Google Scholar
• Khandelwal N FB, Shi F, Spalding J, et al. Health economic outcome analysis of patients randomized in the secure phase 3 trial comparing isavuconazole to voriconazole for primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi Poster [826]. Infectious Disease Week annual meeting; 2014. Philadelphia
   Google Scholar
• Marty F PJ, Cornely O, Mullane K, et al. An open-label phase 3 study of isavuconazole (VITAL): Focus on mucormycosis Poster [824]. Infectious Disease Week annual meeting; 2014. Philadelphia
   Google Scholar
• Cornely A, Rahav G, Maher R, et al. Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp. treated with isavuconazole: Experience from the VITAL and SECURE trials Poster [M-1760]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC). American Society for Microbiology; 2014, Washington
   Google Scholar
• Queiroz-Telles F CO, Perfect J, Kovanda L, et al. Successful outcomes in patients with invasive fungal disease due to C. gattii and C. neoformans treated with isavuconazole: Experience from the vital trial Poster [M-1773]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014, Washington
   Google Scholar
• Isavuconazole (BAL8557) in the treatment of candidemia and other invasive candida infections. Available from: http://clinicaltrials.gov/show/NCT00413218 [Last accessed 22 February 2015]
   Google Scholar
• Thompson GR RA, Santos R, Queiroz-Telles F, et al. Outcomes in patients with invasive fungal disease caused by dimorphic fungi treated with isavuconazole: Experience from the vital trial Poster [M-1775]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014, Washington
   Google Scholar
• Kontoyiannis D GM, Lee M, Nucci M, et al. A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole vs.voriconazole in patients with invasive mold disease (SECURE): Outcomes in invasive aspergillosis patients Oral presentation. Infectious Disease Week annual meeting; 2014. Philadelphia
   Google Scholar
• Patterson T SD, Mullane K, Cornely O, et al. A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole vs. voriconazole in patients with invasive mold disease (SECURE): Outcomes in neutropenic patients. Infectious Disease Week annual meeting; 2014. Philadelphia
   Google Scholar
• Yamazaki T ZN, Pearlman H, Desai A, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of sirolimus in healthy subjects. Clin Pharmacol Ther 2013;93:S114
   Web of Science ®Google Scholar
• Yamazaki T PH, Kowaiski D, Lademacher C, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of cyp3A4 substrate atorvastatin in healthy subjects Poster [A-449]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting.American Society for Microbiology; 2013, Denver
   Google Scholar
• Yamazaki T DA, Kowalski D, Lademacher C, et al. Pharmacokinetic interaction between isavuconazole and a fixed-dose combination of lopinavir 400 mg/ritonavir 100 mg in healthy subjects Poster [772]. Infectious Disease Week annual meeting; 2013. San Francisco
   Google Scholar
• Yamazaki T DA, Pearlman H, Kowalski D, et al. No effect of pharmacokinetic and pharmacodynamic parameters of warfarin after co-administration with isavuconazole Poster [A-448]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. American Society for Microbiology; 2013, Denver
   Google Scholar
• Desai A YT, Lademacher C, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of cyp2D6 substrate dextromethorphan in healthy subjects Poster [R6634]. American Association of Pharmaceutical Scientists National Biotechnology Conference; 2013, San Antonio
   Google Scholar
• Desai A, Pearlman H. Effect of multiple doses of isavuconazole on the pharmacokinetics of cyp2B6 substrate bupropion in healthy subjects Poster [A-450]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting. American Society for Microbiology; 2013, Denver
   Google Scholar
• Desai A YT, Lademacher C, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of methadone in healthy subjects Poster [R6635]. American Association of Pharmaceutical Scientists National Biotechnology Conference; 2013, San Antonio
   Google Scholar
• Desai A PH, Yamazaki T, Lademacher C, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of cyp1A2 substrate caffeine and cyp2C8 substrate repaglinide in healthy subjects Poster [A-696]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC). American Society for Microbiology; 2014, Washington
   Google Scholar
• Schmitt-Hoffmann A RB, Sauer J. Effect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral doses of BAL8557 and rifampicin Poster [P-0319]. 16th congress of the international society for human and animal mycology (ISHAM); 2006, Paris, France
   Google Scholar
• Raad I MK, Selleslag D, Thompson G, et al. A phase 3, randomized, double-blind, non-inferiority trial to evaluate efficacy and safety of isavuconazole vs.voriconazole in patients with invasive mold disease: outcomes in patients with pulmonary infections. Infectious Disease Week annual meeting; 2014. Philadelphia
   Google Scholar